CDC Updates RSV Vaccination Recommendation for Adults
WEBJun 26, 2024 · Today, CDC updated its recommendation for the use of Respiratory Syncytial Virus (RSV) vaccines in people ages 60 and older. For this upcoming respiratory virus season, CDC recommends: Everyone ages 75 and older receive the RSV vaccine.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way.
Why Is RSV Different Now Than In Past Years? - Cleveland Clinic …
WEBMay 31, 2023 · RSV has surged in nearly all populations. According to the U.S. Centers for Disease Control and Prevention (CDC), an estimated 58,000–80,000 children younger than 5 and an estimated 177,000 adults over the age of 60 are hospitalized each year after getting infected with RSV.
Federal Officials Revise Recommendations for R.S.V. Vaccine
WEBJun 26, 2024 · The Food and Drug Administration has approved three R.S.V. vaccines. Two of them, GSK’s Arexvy and Pfizer’s Abrysvo, were approved in May last year and were administered during the fall and...
FDA advisers recommend world's first RSV vaccines, from ... - NBC News
WEBMar 1, 2023 · An FDA advisory committee has recommended that the agency approve two RSV vaccines for older people, one from Pfizer and another from GSK.
RSV Vaccines Are Finally Here after Decades of False Starts
WEBMar 20, 2023 · Pfizer has said its RSV vaccine for pregnant people is 82 percent effective against severe RSV in newborns for up to three months and 69 percent effective through six months. The committee was...
CDC Revises RSV Vaccine Guidelines Over Side Effect Concerns - WebMD
WEBAug 7, 2024 · RSV vaccination is now recommended for all people ages 75 and older. People ages 60 to 74 who are at increased risk for severe disease due to RSV should also get vaccinated.
CDC study shows effectiveness of RSV immunization for infants
WEBMar 7, 2024 · New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).
The race to an RSV vaccine is nearly over as shots await FDA ... - NBC News
WEBFeb 16, 2023 · RSV cases spiked dramatically in the U.S. earlier this winter, which overwhelmed children's hospitals — a reminder of the virus's threat. Since then, the pharmaceutical race to get vaccines to...
CDC and FDA Expedite the Availability of Additional Doses of New RSV …
WEBNov 16, 2023 · Today, CDC announced the release of more than 77,000 additional doses of Beyfortus™ (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.
Skip to content